You are here

Regulation impact statement: General requirements for labels for medicines

Version 3.0, July 2016

10 August 2016

Book pagination

Appendix C: List of submissions received in response to 2015 targeted consultation

45 submissions were received, 38 non-confidential and 7 confidential.

A B C D E G H I J L M N P R S T

A

  • Accord Australasia Ltd
  • Allergy & Anaphylaxis Australia
  • Australasian Society of Clinical and Experimental Pharmacology and Toxicology
  • Australian Medical Association
  • Australian Red Cross Blood Service
  • Australian Self Medication Industry

B

  • Bayer Australia Ltd

C

  • Clinical Excellence Commission
  • Coeliac Australia
  • Communication Research Institute
  • Complementary Medicines Australia

D

  • Department of Health, Queensland
  • Department of Health and Human Services, Tasmania

E

  • Ego Pharmaceuticals Pty Ltd

G

  • Generic and Biosimilar Medicines Association
  • Global Standards 1
  • GlaxoSmithKline
  • GlaxoSmithKline - Consumer Healthcare

H

  • Human factors Specialist, Clinical Excellence Commission

J

  • Johnson & Johnson Pacific Pty Ltd

M

  • Medicines Australia
  • Medicines New Zealand

N

  • National Pharmaceuticals Services Association
  • Nestle Australia
  • New Zealand Self Medication Industry
  • NSW Therapeutic Advisory Group

P

  • Pfizer Australia Pty Ltd
  • Pfizer Consumer Health care
  • Pharmaceutical Defence Limited
  • Pharmacy Board Australia
  • Pharmaceutical Society of Australia

R

  • Reckitt Benckiser

S

  • Smart Prescription Packs
  • Society of Hospital Pharmacists of Australia

T

  • The Pharmacy Guild of Australia
  • The Royal Australian College of General Practitioners
  • The Royal Australian and New Zealand College of Psychiatrists
  • Theo Raynor, Professor, University of Leeds, UK

Book pagination